José Ricardo Pérez

Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER–Medicare Database Analysis

Sumanta K. Pal, Sameer R. Ghate, Nanxin Li et al. · Clinical Genitourinary Cancer · 2017 · 72 citations · Full text

Medicine, Oncology, Precision Oncology +14

Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study

Giorgio V. Scagliotti, P. Kosmidis, Filippo de Marinis et al. · Annals of Oncology · 2012 · 38 citations · Full text

Medicine, Oncology, Pharmacotherapy +3

Results of a Qualitative Study to Develop a Patient Reported Outcome Measure for Patients with 4 Subtypes of Soft Tissue Sarcoma

Anne Skalicky, Sameer R. Ghate, José Ricardo Pérez et al. · Sarcoma · 2017 · 22 citations · Full text

Nursing, Clinical Sciences, Oncology +16

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma

Elyse Swallow, Andrew Messali, Sameer R. Ghate et al. · Journal of Managed Care & Specialty Pharmacy · 2018 · 21 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis

Nicholas J. Vogelzang, Sumanta K. Pal, Sameer R. Ghate et al. · Advances in Therapy · 2017 · 20 citations · Full text

Medicine, Oncology, Pharmacotherapy +16